LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt

Standard

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. / Hagemann, Christoffer A.; Jensen, Malene S.; Holm, Stephanie; Gasbjerg, Lærke S.; Byberg, Sarah; Skov-Jeppesen, Kirsa; Hartmann, Bolette; Holst, Jens J.; Dela, Flemming; Vilsbøll, Tina; Christensen, Mikkel B.; Holst, Birgitte; Knop, Filip K.

I: Cell Reports Medicine, Bind 3, Nr. 4, 100582, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt

Harvard

Hagemann, CA, Jensen, MS, Holm, S, Gasbjerg, LS, Byberg, S, Skov-Jeppesen, K, Hartmann, B, Holst, JJ, Dela, F, Vilsbøll, T, Christensen, MB, Holst, B & Knop, FK 2022, 'LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men', Cell Reports Medicine, bind 3, nr. 4, 100582. https://doi.org/10.1016/j.xcrm.2022.100582

APA

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., Christensen, M. B., Holst, B., & Knop, F. K. (2022). LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 3(4), [100582]. https://doi.org/10.1016/j.xcrm.2022.100582

Vancouver

Hagemann CA, Jensen MS, Holm S, Gasbjerg LS, Byberg S, Skov-Jeppesen K o.a. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine. 2022;3(4). 100582. https://doi.org/10.1016/j.xcrm.2022.100582

Author

Hagemann, Christoffer A. ; Jensen, Malene S. ; Holm, Stephanie ; Gasbjerg, Lærke S. ; Byberg, Sarah ; Skov-Jeppesen, Kirsa ; Hartmann, Bolette ; Holst, Jens J. ; Dela, Flemming ; Vilsbøll, Tina ; Christensen, Mikkel B. ; Holst, Birgitte ; Knop, Filip K. / LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. I: Cell Reports Medicine. 2022 ; Bind 3, Nr. 4.

Bibtex

@article{f527ecf96ade405aa19f99a0bfe5e296,
title = "LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men",
abstract = "The gastric hormone ghrelin stimulates food intake and increases plasma glucose through activation of the growth hormone secretagogue receptor (GHSR). Liver-expressed antimicrobial peptide 2 (LEAP2) has been proposed to inhibit actions of ghrelin through inverse effects on GHSR activity. Here, we investigate the effects of exogenous LEAP2 on postprandial glucose metabolism and ad libitum food intake in a randomized, double-blind, placebo-controlled, crossover trial of 20 healthy men. We report that LEAP2 infusion lowers postprandial plasma glucose and growth hormone concentrations and decreases food intake during an ad libitum meal test. In wild-type mice, plasma glucose and food intake are reduced by LEAP2 dosing, but not in GHSR-null mice, pointing to GHSR as a potential mediator of LEAP2's glucoregulatory and appetite-suppressing effects in mice.",
keywords = "clinical trial, food intake, glucose metabolism, growth hormone secretagogue receptor, liver-expressed antimicrobial peptide 2",
author = "Hagemann, {Christoffer A.} and Jensen, {Malene S.} and Stephanie Holm and Gasbjerg, {L{\ae}rke S.} and Sarah Byberg and Kirsa Skov-Jeppesen and Bolette Hartmann and Holst, {Jens J.} and Flemming Dela and Tina Vilsb{\o}ll and Christensen, {Mikkel B.} and Birgitte Holst and Knop, {Filip K.}",
note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
doi = "10.1016/j.xcrm.2022.100582",
language = "English",
volume = "3",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
number = "4",

}

RIS

TY - JOUR

T1 - LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

AU - Hagemann, Christoffer A.

AU - Jensen, Malene S.

AU - Holm, Stephanie

AU - Gasbjerg, Lærke S.

AU - Byberg, Sarah

AU - Skov-Jeppesen, Kirsa

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Dela, Flemming

AU - Vilsbøll, Tina

AU - Christensen, Mikkel B.

AU - Holst, Birgitte

AU - Knop, Filip K.

N1 - Publisher Copyright: © 2022 The Author(s)

PY - 2022

Y1 - 2022

N2 - The gastric hormone ghrelin stimulates food intake and increases plasma glucose through activation of the growth hormone secretagogue receptor (GHSR). Liver-expressed antimicrobial peptide 2 (LEAP2) has been proposed to inhibit actions of ghrelin through inverse effects on GHSR activity. Here, we investigate the effects of exogenous LEAP2 on postprandial glucose metabolism and ad libitum food intake in a randomized, double-blind, placebo-controlled, crossover trial of 20 healthy men. We report that LEAP2 infusion lowers postprandial plasma glucose and growth hormone concentrations and decreases food intake during an ad libitum meal test. In wild-type mice, plasma glucose and food intake are reduced by LEAP2 dosing, but not in GHSR-null mice, pointing to GHSR as a potential mediator of LEAP2's glucoregulatory and appetite-suppressing effects in mice.

AB - The gastric hormone ghrelin stimulates food intake and increases plasma glucose through activation of the growth hormone secretagogue receptor (GHSR). Liver-expressed antimicrobial peptide 2 (LEAP2) has been proposed to inhibit actions of ghrelin through inverse effects on GHSR activity. Here, we investigate the effects of exogenous LEAP2 on postprandial glucose metabolism and ad libitum food intake in a randomized, double-blind, placebo-controlled, crossover trial of 20 healthy men. We report that LEAP2 infusion lowers postprandial plasma glucose and growth hormone concentrations and decreases food intake during an ad libitum meal test. In wild-type mice, plasma glucose and food intake are reduced by LEAP2 dosing, but not in GHSR-null mice, pointing to GHSR as a potential mediator of LEAP2's glucoregulatory and appetite-suppressing effects in mice.

KW - clinical trial

KW - food intake

KW - glucose metabolism

KW - growth hormone secretagogue receptor

KW - liver-expressed antimicrobial peptide 2

U2 - 10.1016/j.xcrm.2022.100582

DO - 10.1016/j.xcrm.2022.100582

M3 - Journal article

C2 - 35492241

AN - SCOPUS:85128303141

VL - 3

JO - Cell Reports Medicine

JF - Cell Reports Medicine

SN - 2666-3791

IS - 4

M1 - 100582

ER -

ID: 305187282